{"nctId":"NCT04467840","briefTitle":"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia","startDateStruct":{"date":"2020-08-21","type":"ACTUAL"},"conditions":["COVID-19","Lung Infection"],"count":475,"armGroups":[{"label":"Opaganib","type":"EXPERIMENTAL","interventionNames":["Drug: Opaganib"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Opaganib","otherNames":["Yeliva","ABC294640"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Adult male or female ≥18 to ≤80 years of age\n2. Proven COVID-19 infection per RT-PCR assay of a pharyngeal sample (nasopharyngeal or oropharyngeal) AND pneumonia defined as radiographic opacities on chest X-ray or CT scan. that diagnosed COVID-19 pneumonia. Pharyngeal samples collected either at screening or within 7-days prior to screening for the same ongoing COVID-19 pneumonia illness are acceptable\n3. The patient requires, at baseline, high flow supplemental oxygen or positive pressure ventilation or is receiving oxygen via face mask, such as a non-rebreather or reservoir mask, capable of delivering high concentrations of oxygen\n4. Patient agrees to use appropriate methods of contraception during the study and 3 months after the last dose of study drug\n5. The patient or legal representative has signed a written informed consent approved by the IRB/Ethics Committee\n\nExclusion Criteria:\n\n1. Any co-morbidity that may add risk to the treatment in the judgment of the investigator, particularly patients with known cardiac conditions, and serious neuropsychiatric conditions such as psychosis or major depression\n2. Requiring intubation and mechanical ventilation at baseline\n3. Patient has a 'Do Not Intubate' and/or 'Do Not Resuscitate' order in place\n4. Oxygen saturation \\>95% on room air\n5. Any preexisting respiratory condition that requires intermittent or continuous ambulatory oxygen prior to hospitalization\n6. Patient is, in the investigator's clinical judgement, unlikely to survive \\>72 hours\n7. Pregnant (positive serum or urine test within 3 days prior to randomization) or nursing women .\n8. Unwillingness or inability to comply with procedures required in this protocol.\n9. Corrected QT (QTc) interval on electrocardiogram (ECG) \\>470 ms for females or \\>450 ms for males, calculated using Friedericia's formula (QTcF)\n10. AST (SGOT) or ALT (SGPT) \\> 2.0 x upper limit of normal (ULN)\n11. Total bilirubin \\>1.5x ULN (except where bilirubin increase is due to Gilbert's Syndrome)\n12. Serum creatinine \\>2.0 X ULN\n13. Absolute neutrophil count \\<1000 cells/mm3\n14. Platelet count \\<75,000/mm3\n15. Hemoglobin \\<8.0 g/dL\n16. Medications that are sensitive substrates, or substrates with a narrow therapeutic range, for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 CYP2D6 , CYP3A4, P-gP, BCRP and OATP1B1 should be avoided with opaganib\n17. Moderate or strong inhibitors of CYP1A2, CYP3A4, CYP2D6 or P-gP or moderate to strong inducers of CYP3A4 and CYP1A2 are prohibited\n18. Currently taking warfarin, apixaban, argatroban or rivaroxaban due to drug-drug interaction based on CYP450 metabolism\n19. Current drug or alcohol abuse\n20. Currently participating in a clinical study assessing pharmacological treatments, including anti-viral studies\n21. Treatment with any medication that causes QT prolongation within seven days, or 5 half-lives, whichever is longest, prior to initiation of study drug, or intention to use them throughout the study, including but not limited to: amiodarone, amitriptyline, citalopram dose greater than 20 mg/day, dihydroergotamine, disopyramide, dofetilide, dronedarone, ergotamine, ibutilde, ondansetron or other 5-HT3 receptor antagonists, pimozide, procainamide, quinidine, quinine, quinolone, ranolazine, risperidone, sotaloland tolteridine. Investigators are directed to the following up-to-date web site listing QT prolonging drugs: https://www.crediblemeds.org/index.php/drugsearch","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Supplemental Oxygen Requirement","description":"To compare the proportion of patients no longer requiring supplemental oxygen for at least 24 hours by Day 14 between subjects taking opaganib and those on placebo.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"132","spread":null}]},{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With ≥ 2 Category Improvement on the World Health Organization (WHO) Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42","description":"Compare ≥2 category improvement on the WHO Ordinal Scale for Clinical Improvement from 0(uninfected) to 8(death) for subjects taking opaganib and those on placebo, lower scores indicate improvement. Success was defined as subject who reached improvement of at least two points on the WHO Ordinal Scale by Day 14, maintained by the end of study visit, and failure otherwise.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"138","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Improvement to a Score of 3 or Less on the WHO Ordinal Scale for Clinical Improvement With a Scale Ranging From 8 Down to 0","description":"Compare scores of subjects taking opaganib and those on placebo, lower scores indicate improvement to determine time to recovery as defined by improvement to a score of 3 or less on the WHO Ordinal Scale for Clinical Improvement with a scale ranging from 0 (uninfected) to 8 (death)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"138","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Low Oxygen Flow Via Nasal Cannula","description":"To compare the time to low oxygen flow via nasal cannula e.g. from high oxygen flow via nasal cannula or CPAP, if high oxygen flow is not an available option between subjects taking opaganib and those on placebo.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"167","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Discharge From Hospital Measured at 14 Days","description":"Time to subject discharge from hospital","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.50","spread":null},{"groupId":"OG001","value":"14.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients Requiring Intubation and Mechanical Ventilation by Day 42","description":"To compare the proportion of patients requiring intubation and mechanical ventilation between subjects taking opaganib and those on placebo.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"177","spread":null},{"groupId":"OG001","value":"176","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Two Consecutive Negative Swabs for SARS-CoV-2 at Day 14","description":"To compare the number of patients with two consecutive negative swabs for SARS-CoV-2 by PCR at Day 14 between subjects taking opaganib and those on placebo.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Patients With Negative Swabs for SARS-CoV-2 at Day 14","description":"To compare the proportion of patients with two consecutive negative swabs for SARS-CoV-2 by PCR at Day 14 between subjects taking opaganib and those on placebo.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"79","spread":null}]},{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality Due to Any Cause","description":"To compare mortality 28 days post-baseline between subjects taking opaganib and those taking placebo","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"189","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality Due to Any Cause","description":"To compare mortality 42 days post-baseline between subjects taking opaganib and those taking placebo","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"186","spread":null},{"groupId":"OG001","value":"186","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","description":"To compare the number of participants with treatment emergent adverse events (TEAEs) in patients with severe COVID-19 pneumonia between participants taking opaganib and participants taking placebo","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]}]},{"type":"POST_HOC","title":"Supplemental Oxygen Requirement in the ≤60% FiO2 Sub-population","description":"Percentage of Subjects No Longer Requiring Supplemental Oxygen, for at Least 24 Hours by Day 14 in the ≤60% FiO2 FiO2 Sub-populations","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"POST_HOC","title":"Supplemental Oxygen Requirement in the > 60% FiO2 Sub-population","description":"Percentage of Subjects No Longer Requiring Supplemental Oxygen, for at Least 24 Hours by Day 14 in the \\> 60% FiO2 FiO2 Sub-populations","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]},{"type":"POST_HOC","title":"Subjects With ≥ 2 Category Improvement on the WHO Ordinal Scale for Clinical Improvement by Day 14 Maintained to Day 42 in the FiO2 ≤ 60% Population","description":"Post hoc analysis in the FiO2 ≤ 60% population. Compare ≥2 category improvement on the WHO Ordinal Scale for subjects taking opaganib and those on placebo, lower scores indicate improvement. Success was defined as subject who reached improvement of at least two points on the WHO Ordinal Scale by Day 14, maintained by the end of study visit day 42, and failure otherwise. WHO Ordinal Scale for Clinical Improvement is a scale from 0 (uninfected) to 8 (death) with higher scale poorer clinical status","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"POST_HOC","title":"Subjects With ≥ 2 Category Improvement on the WHO Ordinal Scale for Clinical Improvement by Day 14 up to Day 42 in the FiO2 > 60% Population","description":"Post hoc analysis in the FiO2 \\> 60% population. Compare ≥2 category improvement on the WHO Clinical Ordinal Scale for subjects taking opaganib and those on placebo, lower scores indicate improvement. Success was defined as subject who reached improvement of at least two points on the WHO Ordinal Scale by Day 14, maintained by the end of study visit day 42 and failure otherwise.WHO Scale 0 to 8 with 8 death and higher number worse clinical state","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"POST_HOC","title":"Number of Subjects With Improvement to a Score of 3 or Less on the WHO Ordinal Scale for Clinical Improvement in the FiO2 ≤60% Population","description":"Compare scores of subjects taking opaganib and those on placebo, lower scores indicate improvement.\n\nWHO Ordinal Scale for Clinical Improvement with a scale ranging from 8 down to 0 with a higher score indicating a poorer clinical status","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]}]},{"type":"POST_HOC","title":"Number of Subjects With Improvement to a Score of 3 or Less on the WHO Ordinal Scale for Clinical Improvement in the FiO2 > 60% Population","description":"Compare scores of subjects taking opaganib and those on placebo, lower scores indicate improvement.\n\nWorld Health Organization Ordinal Scale for Clinical Improvement with a scale ranging from 8 down to 0 with a higher score indicating poorer clincal status","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"POST_HOC","title":"Number of Subjects Discharged From Hospital in the FiO2 ≤60% Population","description":"Subjects discharged from the hospital in the FiO2 ≤60% population at 14 days","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"POST_HOC","title":"Number of Subjects Discharged From Hospital in the FiO2 > 60% Population","description":"Number of subjects discharged from the hospital in the FiO2 \\> 60% population","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"POST_HOC","title":"Requiring Intubation and Mechanical Ventilation by Day 42 in the FiO2 ≤60% Population","description":"To compare the proportion of patients in the FiO2 ≤60% sub-population requiring intubation and mechanical ventilation between subjects taking opaganib and those on placebo.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"POST_HOC","title":"Requiring Intubation and Mechanical Ventilation by Day 42 in the FiO2 > 60% Population","description":"To compare the proportion of patients in the FiO2 \\> 60% sub-population requiring intubation and mechanical ventilation between subjects taking opaganib and those on placebo.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"POST_HOC","title":"Mortality Due to Any Cause in the FiO2 ≤60% Population","description":"To compare mortality 28 and 42 days post-baseline between subjects taking opaganib and those taking placebo in the in the FiO2 ≤60% population","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"110","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]}]},{"type":"POST_HOC","title":"Mortality Due to Any Cause in the FiO2 > 60% Population","description":"To compare mortality 28 and 42 days post-baseline between subjects taking opaganib and those taking placebo in the in the FiO2 \\> 60% population","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"24","spread":null}]},{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":52,"n":230},"commonTop":["Constipation","Alanine aminotransferase increased","Insomnia","Hyperkalaemia","Nausea"]}}}